Drug Information

Drug General Information
Drug ID
D04YCJ
Former ID
DNC006060
Drug Name
1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527952]
Formula
C10H12FN3O
Canonical SMILES
CC(CN1C2=C(C(=O)C=CC2=CN1)F)N
InChI
1S/C10H12FN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,13H,5,12H2,1H3/t6-/m0/s1
InChIKey
VDSYFCJRTCTNBV-LURJTMIESA-N
PubChem Compound ID
11506721
Target and Pathway
Target(s) 5-hydroxytryptamine 2C receptor Target Info Inhibitor [527952]
5-hydroxytryptamine 2B receptor Target Info Inhibitor [527952]
5-hydroxytryptamine 2A receptor Target Info Inhibitor [527952]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
SIDS Susceptibility Pathways
GPCR downstream signaling
GPCRs, Other
References
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.